Market Place
Sourcing Support
All News #Library
Others
Astellas takes $540M impairment charge over Audentes` gene therapy trial hold
28 Apr 2021 //
FIERCE BIOTECH
Audentes Becomes Astellas Gene Therapies, Will Advance MD Treatments
02 Apr 2021 //
MUSCULARDYSTROPHYNEWS
Audentes CEO exits as Astellas rebrands a gene therapy buyout
01 Jan 2021 //
BIOPHARMADIVE
Audentes sees FDA hold lifted after 3 trial deaths
31 Dec 2020 //
FIERCE BIOTECH
Audentes sees FDA hold lifted after 3 trial deaths blighted $3B program
29 Dec 2020 //
FIERCE BIOTECH
Taysha Gene Therapies Builds Experienced Executive Leadership Team
31 Aug 2020 //
BUSINESSWIRE
Astellas` Audentes reports 3rd death in gene therapy trial
22 Aug 2020 //
FIERCE BIOTECH
Audentes says third study patient passed away in ASPIRO trial evaluating AT132
21 Aug 2020 //
PHARMABIZZ
Audentes Provides Update on the ASPIRO Clinical Trial Evaluating AT132
21 Aug 2020 //
BUSINESSWIRE
Phase 1/2 Trial of Gene Therapy AT845 Recruiting Patients With Late-onset Pompe
05 Aug 2020 //
POMPDISEASESNEWS
After patients die, FDA clamps hold on Astellas gene therapy
30 Jun 2020 //
FIERCE BIOTECH
Two patients die in now-halted study of Audentes gene therapy
29 Jun 2020 //
BIOPHARMADIVE
Audentes CEO Holles on keeping the biotech spirit
13 Jun 2020 //
FIERCE BIOTECH
Audentes investing $109M in gene therapy manufacturing facility
19 Feb 2020 //
FIERCE PHARMA
Audentes to build new gene therapy plant in North Carolina
18 Feb 2020 //
BIOPHARMADIVE
Astellas Completes Acquisition of Audentes Therapeutics
16 Jan 2020 //
PR NEWSWIRE
Furtive whispers and a bidding war: Inside Astellas’ $3B buyout of Audentes
18 Dec 2019 //
FIERCEPHARMA
Inside Astellas` $3B Audentes gene therapy acquisition: coded messages
16 Dec 2019 //
ENDPTS
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
03 Dec 2019 //
PRESS RELEASE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.